stockrow
Monday 9 November 2026
Export TRDA’s income statement to Excel — free account
Entrada Therapeutics, Inc.
TRDAEntrada Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $25.4 million, down 87.9% from fiscal 2024.
- Revenue
- −43.9%
- EPS
- +11.3%
- Free cash flow
- −7.05%
Quarter to September 2026, against a year earlier
4.89
0.34
+7.47%
Follow TRDA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 129 | 211 | 25 | 4 | (55.6%) | 3 | 20 | 20 | (7.8%) | |
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 100.00 | 100.00 | 100.00 | 100.00 | +100.0 pt | ||||||
| EBT | — | — | — | (5) | (27) | (51) | (95) | 12 | 66 | (143) | (161) | +74.3% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 9.34 | 31.54 | (561.84) | (4,053.16) | (561.8) pt | ||||||
| Net income | — | 0 | — | (5) | (27) | (51) | (95) | (7) | 66 | (144) | (161) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 3.90 | 5.65 | 0.61 | 0.09 | n/m | |||||
| Earnings | — | — | — | (5.47) | (24.00) | (8.16) | (3.02) | (0.20) | 1.76 | (3.47) | (3.84) | (7.3%) | ||||||
| Cash flow | — | — | — | (11.58) | (23.13) | (8.11) | (3.00) | 4.23 | (1.11) | (3.11) | (3.22) | (19.7%) | ||||||
| Capex | — | — | — | (0.68) | (2.10) | (0.73) | (0.09) | (0.17) | (0.08) | (0.03) | 0.00 | (42.2%) | ||||||
| Free cash flow | — | — | — | (12.25) | (25.23) | (8.85) | (3.09) | 4.06 | (1.20) | (3.13) | (3.22) | (20.3%) | ||||||
| Book value | — | — | — | 17.47 | 36.34 | 47.66 | 6.79 | 7.33 | 11.49 | 7.40 | 4.68 | (13.3%) | ||||||
| Shares, m | — | — | — | 1 | 1 | 6 | 31 | 33 | 37 | 41 | 42 | +88.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 8.69 | 0.00 | 0.00 | 2.9 | |||||
| P/S | — | — | — | — | — | — | — | 3.89 | 3.06 | 16.73 | 52.10 | 7.9 | ||||||
| P/B | — | — | — | — | — | — | — | 2.07 | 1.50 | 1.39 | 1.04 | 1.7 | ||||||
| EV/Sales | — | — | — | — | — | — | — | 1.16 | 1.07 | 5.07 | 3.57 | 2.4 | ||||||
| EV/FCF | — | — | — | — | — | — | — | 1.11 | (5.03) | (1.00) | (0.10) | (1.6) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (11) | (26) | (51) | (94) | 140 | (42) | (129) | (136) | +51.1% | |||||
| Capex | — | — | — | (1) | (2) | (5) | (3) | (6) | (3) | (1) | 0 | +8.7% | ||||||
| Free cash flow | — | — | — | (11) | (28) | (55) | (97) | 134 | (45) | (130) | (136) | +49.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 16 | 37 | 292 | 188 | 211 | 401 | 282 | 177 | +62.1% | |||||
| Net debt | — | — | — | (17) | (39) | (291) | (189) | (352) | (420) | (296) | (193) | +61.3% | ||||||
| Shareholders’ equity | — | — | — | 16 | 40 | 299 | 213 | 242 | 429 | 306 | 198 | +63.0% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (55.93) | (85.88) | (29.29) | (33.92) | (1.85) | 13.18 | (31.81) | (47.48) | +24.1 pt | |||||
| ROIC | — | — | — | 0.00 | (1,484.14) | (417.49) | (254.93) | 0.00 | 338.50 | (1,009.37) | (2,008.96) | (1,009.4) pt | ||||||
| ROE | — | — | — | 17.89 | 93.05 | (39.78) | (37.01) | (2.94) | 19.56 | (39.13) | (59.88) | (57.0) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 78 | 114 | 130 | 159 | 183 | 152 | — | +14.3% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.81 | 1.15 | 0.17 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026
Entrada Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| TRDA Entrada Therapeutics, Inc. | $191.5M | — (loss-making) | — (loss-making) | −43.93% (below 0%: shrinking) | n/m | −7.05% (below 0%: shrinking) | 100.00% | (4,606.52%) | |
| CGEN Compugen Ltd. | $185.7M | 5.2× | — (loss-making) | +107.00% (above 0%: growing) | n/m | −155.42% (below 0%: shrinking) | (3.54%) | (339.62%) | Compare |
| MDWD MediWound Ltd. | $184.0M | — (loss-making) | — (loss-making) | −45.83% (below 0%: shrinking) | n/m | −49.90% (below 0%: shrinking) | 10.90% | (305.89%) | Compare |
| BCYC Bicycle Therapeutics PLC Sponsored ADR | $182.5M | — (loss-making) | — (loss-making) | +190.24% (above 0%: growing) | n/m | +43.48% (above 0%: growing) | 100.00% | (39.57%) | Compare |
| ACOG Alpha Cognition Inc. | $180.5M | — (loss-making) | — (loss-making) | +267.56% (above 0%: growing) | n/m | −109.25% (below 0%: shrinking) | 94.80% | (127.29%) | Compare |
| WHWK Whitehawk Therapeutics, Inc. | $178.4M | — (loss-making) | — (loss-making) | +33.48% (above 0%: growing) | n/m | +72.57% (above 0%: growing) | 89.36% | 0.00% | Compare |
| UPB Upstream Bio, Inc. | $176.9M | — (loss-making) | — (loss-making) | −17.50% (below 0%: shrinking) | n/m | +9.33% (above 0%: growing) | 100.00% | (5,480.98%) | Compare |
| IVVD Invivyd, Inc. | $166.0M | — (loss-making) | — (loss-making) | +21.20% (above 0%: growing) | n/m | −226.89% (below 0%: shrinking) | 91.09% | (320.76%) | Compare |
| BBOT BridgeBio Oncology Therapeutics, Inc | $163.6M | — (loss-making) | — | — | n/m | −88.78% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $179.5M | — | — | +33.48% | — | −69.34% | 91.09% | (216.59%) |
Pay and ownership Proxy statement filed 24 April 2026
Ownership
Directors and executive officers, together
9.49%
Entities affiliated with Baker Bros. Advisors LP
19.51%
Entities affiliated with MPM Capital
11.40%
Entities affiliated with
10.45%
Roche Finance Ltd
6.62%
BlackRock, Inc.
5.09%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement